Logo Logo
Eine Ebene nach oben
Exportieren als [feed] RSS 1.0 [feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 42 .

Zeitschriftenartikel

Pfirrmann, Markus, Evtimova, D., Saussele, S., Castagnetti, F., Cervantes, F., Janssen, Jan, Hoffmann, Verena, Gugliotta, G., Hehlmann, R., Hochhaus, A., Hasford, Joerg and Baccarani, M. (12. Januar 2017): No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. In: Journal of Cancer Research and Clinical Oncology, Vol. 143, Nr. 5: S. 843-850

Schütz, C., Inselmann, S., Saussele, Susanne, Dietz, C. T., Müller, M. C., Brendel, C. A., Metzelder, S. K., Brümmendorf, Tim H., Waller, C., Dengler, J., Goebeler, M. E., Herbst, R., Hanzel, S., Freunek, G., Illmer, T., Wang, Y., Lange, T., Finkernagel, F., Hehlmann, R., Huber, M., Neubauer, A., Hochhaus, A., Guilhot, J., Xavier Mahon, F., Pfirrmann, Markus and Burchert, A. (2017): Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. In: Leukemia, Vol. 31: S. 829-836

Pfirrmann, Markus, Baccarani, M., Saußele, Susanne, Guilhot, J., Cervantes, F., Ossenkoppele, G., Hoffmann, V. S., Castagnetti, F., Hasford, Joerg, Hehlmann, R. and Simonsson, B. (2016): Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. In: Leukemia, Vol. 30, Nr. 1: S. 48-56

Miranda, M. B., Lauseker, Michael, Kraus, M. P., Proetel, U., Hanfstein, B., Fabarius, A., Baerlocher, Gabriela M., Heim, D., Hossfeld, D. K., Kolb, H. J., Krause, S. W., Nerl, C., Brümmendorf, Tim H., Verbeek, W., Fauser, A. A., Prummer, O., Neben, K., Hess, U., Mahlberg, R., Ploger, C., Flasshove, M., Rendenbach, B., Hofmann, W. K., Muller, M. C., Pfirrmann, Markus, Hochhaus, A., Hasford, Joerg, Hehlmann, R. and Saußele, Susanne (2016): Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. In: Leukemia, Vol. 30, Nr. 6: S. 1255-1262

Kossak-Roth, U., Saußele, Susanne, Aul, C., Büchner, T., Dohner, H., Dugas, Martin, Ehninger, G., Ganser, A., Giagounidis, A., Gökbuget, Nicola, Griesshammer, M., Hasford, Joerg, Heuser, M., Hiddemann, Wolfgang, Hochhaus, A., Hoelzer, D., Niederwieser, D. W., Reiter, A., Röllig, C. and Hehlmann, R. (2016): Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL). In: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, Vol. 59, Nr. 4: S. 444-453

Gratwohl, A., Pfirrmann, Markus, Zander, A., Kröger, N., Beelen, D., Novotny, J., Nerl, C., Scheid, C., Spiekermann, Karsten, Mayer, J., Sayer, H. G., Falge, C., Bunjes, D., Döhner, H., Ganser, A., Schmidt-Wolf, I., Schwerdtfeger, R., Baurmann, H., Kuse, R., Schmitz, N., Wehmeier, A., Fischer, J. T., Ho, A. D., Wilhelm, M., Goebeler, M. E., Lindemann, H. W., Bormann, M., Hertenstein, B., Schlimok, G., Baerlocher, Gabriela M., Aul, C., Pfreundschuh, M., Fabian, M., Staib, P., Edinger, M., Schatz, M., Fauser, A., Arnold, R., Kindler, T., Wulf, G., Rosselet, A., Hellmann, A., Schäfer, E., Prümmer, O., Schenk, M., Hasford, Joerg, Heimpel, H., Hossfeld, D. K., Kolb, H.-J., Büsche, G., Haferlach, C., Schnittger, S., Müller, M. C., Reiter, A., Berger, Ute, Saußele, Susanne, Hochhaus, A. and Hehlmann, R. (2016): Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. In: Leukemia, Vol. 30, Nr. 3: S. 562-569

Hoffmann, V. S., Baccarani, M., Hasford, Joerg, Castagnetti, F., Raimondo, F. di, Simonsson, B., Indrak, K., Sninska, Z., Sacha, T., Clark, R., Bogdanovic, A., Hellmann, A., Griskevicius, L., Schubert-Fritschle, Gabriele, Sertic, D., Guilhot, J., Lejniece, S., Zupan, I., Burgstaller, S., Koskenvesa, P., Everaus, H., Costeas, P., Lindörfer, Doris, Rosti, G., Saussele, S., Hochhaus, A., Hehlmann, R., Turkina, A. and Casado, L. F. (2016): Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. In: Leukemia, Vol. 31, Nr. 3: S. 593-601

Lauseker, Michael, Hasford, Joerg, Hoffmann, V. S., Mueller, M. C., Hehlmann, R. and Pfirrmann, Markus (2015): A multi-state model approach for prediction in chronic myeloid leukaemia. In: Annals of Hematology, Vol. 94, Nr. 6: S. 919-927

Saußele, Susanne, Krauß, M. P., Hehlmann, R., Lauseker, Michael, Proetel, U., Kalmanti, L., Hanfstein, B., Fabarius, A., Kraemer, D., Berdel, W. E., Bentz, M., Staib, P., de Wit, M., Wernli, M., Zettl, F., Hebart, H. F., Hahn, M., Heymanns, J., Schmidt-Wolf, I., Schmitz, N., Eckart, M. J., Gassmann, W., Bartholomäus, A., Pezzutto, A., Oppliger Leibundgut, E., Heim, D., Krause, S. W., Burchert, A., Hofmann, W. K., Hasford, Joerg, Hochhaus, A., Pfirrmann, Markus and Müller, M. C. (2015): Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. In: Blood, Vol. 126, Nr. 1: S. 42-49

Fabarius, A., Kalmanti, L., Dietz, C. T., Lauseker, Michael, Rinaldetti, S., Haferlach, C., Göhring, G., Schlegelberger, B., Jotterand, M., Hanfstein, B., Seifarth, W., Hänel, M., Köhne, C. H., Lindemann, H. W., Berdel, W. E., Staib, P., Müller, M. C., Proetel, U., Balleisen, L., Goebeler, M. E., Dengler, J., Falge, C., Kanz, L., Burchert, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, Karsten, Brümmendorf, Tim H., Edinger, M., Hofmann, W. K., Pfirrmann, Markus, Hasford, Joerg, Krause, S., Hochhaus, A., Saußele, Susanne and Hehlmann, R. (2015): Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. In: Annals of Hematology, Vol. 94, Nr. 12: S. 2015-2024

Hoffmann, V. S., Baccarani, M., Hasford, Joerg, Lindörfer, Doris, Burgstaller, S., Sertic, D., Costeas, P., Mayer, J., Indrak, K., Everaus, H., Koskenvesa, P., Guilhot, J., Schubert-Fritschle, Gabriele, Castagnetti, F., Di Raimondo, F., Lejniece, S., Griskevicius, L., Thielen, N., Sacha, T., Hellmann, A., Turkina, A. G., Zaritskey, A., Bogdanovic, A., Sninska, Z., Zupan, I., Steegmann, J. L., Simonsson, B., Clark, R. E., Covelli, A., Guidi, G. and Hehlmann, R. (2015): The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. In: Leukemia, Vol. 29, Nr. 6: S. 1336-1343

Kalmanti, L., Saußele, Susanne, Lauseker, Michael, Muller, M. C., Dietz, C. T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S. W., Rinaldetti, S., Dengler, J., Falge, C., Oppliger-Leibundgut, E., Burchert, A., Neubauer, A., Kanz, L., Stegelmann, F., Pfreundschuh, M., Spiekermann, Karsten, Scheid, C., Pfirrmann, Markus, Hochhaus, A., Hasford, Joerg and Hehlmann, R. (2015): Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. In: Leukemia, Vol. 29, Nr. 5: S. 1123-1132

Hanfstein, B., Shlyakhto, V., Lauseker, Michael, Hehlmann, R., Saussele, S., Dietz, C. T., Erben, P., Fabarius, A., Proetel, U., Schnittger, S., Krause, S. W., Schubert, J., Einsele, H., Hänel, M., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Baerlocher, G. M., Pfirrmann, Markus, Hasford, Joerg, Hofmann, W. K., Hochhaus, A. and Muller, M. C. (Oktober 2014): Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. In: Leukemia, Vol. 28, Nr. 10: S. 1988-1992

Pfirrmann, Markus, Saussele, S., Hochhaus, A., Reiter, A., Berger, U., Hossfeld, D. K., Nerl, C., Scheid, C., Spiekermann, K., Mayer, J., Hellmann, A., Lechner, K., Falge, C., Sayer, H. G., Bunjes, D., Ganser, A., Beelen, D. W., Baldomero, H., Schanz, U., Heimpel, H., Kolb, H. J., Hasford, Joerg, Gratwohl, A. and Hehlmann, R. (August 2014): Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. In: Journal of Cancer Research and Clinical Oncology, Vol. 140, Nr. 8: S. 1367-1381

Kalmanti, L., Saußele, Susanne, Lauseker, Michael, Proetel, U., Muller, M. C., Hanfstein, B., Schreiber, A., Fabarius, A., Pfirrmann, Markus, Schnittger, S., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, Karsten, Krause, S. W., Heim, D., Nerl, C., Hossfeld, D. K., Kolb, H. J., Hochhaus, A., Hasford, Joerg and Hehlmann, R. (2014): Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. In: Annals of Hematology, Vol. 93, Nr. 1: S. 71-80

Hehlmann, R., Müller, M. C., Lauseker, Michael, Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, Markus, Haferlach, C., Schnittger, S., Einsele, H., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, Karsten, Baerlocher, Gabriela M., Ehninger, G., Heim, D., Heimpel, H., Nerl, C., Krause, S. W., Hossfeld, D. K., Kolb, H. J., Hasford, Joerg, Saußele, Susanne and Hochhaus, A. (2014): Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. In: Journal of Clinical Oncology, Vol. 32, Nr. 5: S. 415-423

Büchner, T., Schlenk, R. F., Schaich, M., Doehner, K., Krahl, R., Krauter, J., Heil, G., Krug, U., Sauerland, M. C., Heinecke, A., Späth, Daniela, Kramer, M., Scholl, S., Berdel, W. E., Hiddemann, Wolfgang, Hoelzer, D., Hehlmann, R., Hasford, Joerg, Hoffmann, V. S., Doehner, H., Ehninger, G., Ganser, A., Niederwieser, D. W. and Pfirrmann, Markus (2012): Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm‐Combined Prospective Analysis by the German AML Intergroup. In: Journal of Clinical Oncology, Vol. 30, Nr. 29: S. 3604-3610

Hoffmann, Verena, Baccarani, M., Hasford, Joerg, Guilhot, J., Saußele, Susanne, Rosti, G., Guilhot, F., Porkka, K., Ossenkoppele, G., Lindörfer, Doris, Simonsson, B., Pfirrmann, Markus and Hehlmann, R. (2012): The EUTOS CML score aims to support clinical decision-making. In: Blood, Vol. 119, Nr. 12: S. 2966-2967

Hanfstein, B., Müller, M. C., Hehlmann, R., Erben, P., Lauseker, Michael, Fabarius, A., Schnittger, S., Haferlach, C., Göhring, G., Proetel, U., Kolb, H. J., Krause, S. W., Hofmann, W. K., Schubert, J., Einsele, H., Dengler, J., Hänel, M., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Branford, S., Hughes, T. P., Spiekermann, Karsten, Baerlocher, Gabriela M., Pfirrmann, Markus, Hasford, Joerg, Saußele, Susanne and Hochhaus, A. (2012): Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). In: Leukemia, Vol. 26, Nr. 9: S. 2096-2102

Pfirrmann, Markus, Hochhaus, A., Lauseker, Michael, Saußele, Susanne, Hehlmann, R. and Hasford, Joerg (2011): Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. In: Leukemia, Vol. 25, Nr. 9: S. 1433-1438

Fabarius, A., Leitner, A., Hochhaus, A., Müller, M. C., Hanfstein, B., Haferlach, C., Göhring, G., Schlegelberger, B., Jotterand, M., Reiter, A., Jung-Munkwitz, S., Proetel, U., Schwaab, J., Hofmann, W. K., Schubert, J., Einsele, H., Ho, A. D., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, Karsten, Baerlocher, Gabriela M., Lauseker, Michael, Pfirrmann, Markus, Hasford, Joerg, Saußele, Susanne and Hehlmann, R. (2011): Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. In: Blood, Vol. 118, Nr. 26: S. 6760-6768

Hehlmann, R., Grimwade, D., Simonsson, B., Apperley, J., Baccarani, M., Barbui, T., Barosi, G., Bassan, R., Béné, M. C., Berger, Ursula, Büchner, T., Burnett, A., Cross, N. C., de Witte, T. J., Dohner, H., Dombret, H., Einsele, H., Engelich, G., Foa, R., Fonatsch, C., Gökbuget, Nicola, Gluckman, E., Gratwohl, A., Guilhot, F., Haferlach, C., Haferlach, T., Hallek, M., Hasford, Joerg, Hochhaus, A., Hoelzer, D., Kiladjian, J. J., Labar, B., Ljungman, P., Mansmann, Ulrich, Niederwieser, D. W., Ossenkoppele, G., Ribera, J. M., Rieder, H., Serve, H., Schrotz-King, P., Sanz, M. A. and Saußele, Susanne (2011): The European LeukemiaNet: achievements and perspectives. In: Haematologica, Vol. 96, Nr. 1: S. 156-162

Hehlmann, R., Lauseker, Michael, Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., Hänel, M., Pfirrmann, Markus, Krause, S. W., Nerl, C., Pralle, H., Gratwohl, A., Hossfeld, D. K., Hasford, Joerg, Hochhaus, A. and Saußele, Susanne (2011): Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. In: Journal of Clinical Oncology, Vol. 29, Nr. 12: S. 1634-1642

Hasford, Joerg, Baccarani, M., Hoffmann, Verena, Guilhot, J., Saußele, Susanne, Rosti, G., Guilhot, F., Porkka, K., Ossenkoppele, G., Lindörfer, Doris, Simonsson, B., Pfirrmann, Markus and Hehlmann, R. (2011): Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. In: Blood, Vol. 118, Nr. 3: S. 686-692

Saußele, Susanne, Lauseker, Michael, Gratwohl, A., Beelen, D. W., Bunjes, D., Schwerdtfeger, R., Kolb, H. J., Ho, A. D., Falge, C., Holler, E., Schlimok, G., Zander, A. R., Arnold, R., Kanz, L., Dengler, R., Haferlach, C., Schlegelberger, B., Pfirrmann, Markus, Müller, M. C., Schnittger, S., Leitner, A., Pletsch, N., Hochhaus, A., Hasford, Joerg and Hehlmann, R. (2010): Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. In: Blood, Vol. 115, Nr. 10: S. 1880-1885

Rohrbacher, M., Berger, Ursula, Hochhaus, A., Metzgeroth, G., Adam, K., Lahaye, T., Saußele, Susanne, Muller, M. C., Hasford, Joerg, Heimpel, H. and Hehlmann, R. (2009): Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. In: Leukemia, Vol. 23, Nr. 3: S. 602-604

Kreil, S., Pfirrmann, Markus, Haferlach, C., Waghorn, K., Chase, A., Hehlmann, R., Reiter, A., Hochhaus, A. and Cross, NC. (2007): Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. In: Blood, Vol. 110, Nr. 4: S. 1283-1290

Hehlmann, R., Berger, Ursula, Pfirrmann, Markus, Heimpel, H., Hochhaus, A., Hasford, Joerg, Kolb, H. J., Lahaye, T., Maywald, O., Reiter, A., Hossfeld, D. K., Huber, C., Löffler, H., Pralle, H., Queisser, W., Tobler, A., Nerl, C., Solenthaler, M., Goebeler, M. E., Grieshammer, M., Fischer, T., Kremers, S., Eimermacher, H., Pfreundschuh, M., Hirschmann, W. D.., Lechner, K., Wassmann, B., Falge, C., Kirchner, H. H.. and Gratwohl, A. (2007): Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. In: Blood, Vol. 109, Nr. 11: S. 4686-4692

Maywald, O., Pfirrmann, Markus, Berger, Ursula, Breitscheidel, L., Gratwohl, A., Kolb, H. J., Beelen, D. W., Tobler, A., Metzgeroth, G., Gnad, S. U., Hochhaus, A., Hasford, Joerg, Hehlmann, R. and Reiter, A. (2006): Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia. In: Leukemia, Vol. 20, Nr. 3: S. 477-484

Saußele, Susanne, Adam, K., Hochhaus, A., Béné, M. C., Büchner, T., Burnett, A., Finazzi, G., Fonatsch, C., Gluckman, E., Gökbuget, Nicola, Grimwade, D. J., Haferlach, T., Hallek, M., Hasford, Joerg, Hoelzer, D., Ljungman, P., Niederwieser, D. W., Serve, H., Simonsson, B., de Witte, T. J. and Hehlmann, R. (2006): Klinische Forschung im „European LeukemiaNet”. In: Deutsche Medizinische Wochenschrift - DMW, Vol. 131, Nr. 43: S. 2423-2426

Berger, Ursula, Maywald, O., Pfirrmann, Markus, Lahaye, T., Hochhaus, A., Reiter, A., Hasford, Joerg, Heimpel, H., Hossfeld, D. K., Kolb, H. J., Löffler, H., Pralle, H., Queisser, W., Hehlmann, R. and Kolb, H.-J. (2005): Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. In: Leukemia, Vol. 19, Nr. 6: S. 984-989

Hasford, Joerg, Pfirrmann, Markus, Shepherd, P., Guilhot, J., Hehlmann, R., Mahon, F. X., Kluin-Nelemans, H. C., Ohnishi, K., Steegmann, J. L. and Thaler, J. (2005): The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. In: Haematologica, Vol. 90, Nr. 3: S. 335-340

Buesche, G., Freund, M., Hehlmann, R., Georgii, A., Ganser, A., Hecker, H., Heimpel, H., Fonatsch, C., Heinze, B., Pfirrmann, Markus, Holgado, S., Schmeil, A., Tobler, A., Hasford, Joerg, Buhr, T. and Kreipe, H. H. (2004): Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. In: Leukemia, Vol. 18, Nr. 9: S. 1460-1467

Hehlmann, R., Berger, U., Aul, C., Büchner, Th, Dohner, H., Ehninger, G., Ganser, A., Gökbuget, Nicola, Hoelzer, D., Überla, Karl, Gassmann, W., Ludwig, W. D., Rieder, H., Kneba, M., Hochhaus, A., Reiter, A., Hiddemann, W., Ottmann, O. G., Germing, U., Adelhard, K., Dugas, M., Dirschedl, P., Messerer, D., Böhme, A., Harrison-Neu, E., Griesshammer, M., Kienast, J., Kolb, H. J., Ho, A. D., Hallek, M., Neubauer, A., Schlegelberger, B., Niederwieser, D., Heil, G., Muller, T. and Hasford, Joerg (2004): The German competence network 'Acute and chronic leukemias'. In: Leukemia, Vol. 18, Nr. 4: S. 665-669

Buesche, G., Hehlmann, R., Hecker, H., Heimpel, H., Heinze, B., Schmeil, A., Pfirrmann, Markus, Gomez, G., Tobler, A., Herrmann, H., Kappler, M., Hasford, Joerg, Buhr, T., Kreipe, H. H. and Georgii, A. (2003): Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. In: Leukemia, Vol. 17, Nr. 12: S. 2444-2453

Berger, Ursula, Engelich, G., Maywald, O., Pfirrmann, Markus, Hochhaus, A., Reiter, A., Metzgeroth, G., Gnad, U., Hasford, Joerg, Heinze, B., Heimpel, H., Hossfeld, D. K., Kolb, H.-J., Löffler, H., Pralle, H., Queisser, W. and Hehlmann, R. (2003): Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. In: Leukemia, Vol. 17, Nr. 9: S. 1820-1826

Hehlmann, R., Berger, Ursula, Pfirrmann, Markus, Hochhaus, A., Metzgeroth, G., Maywald, O., Hasford, Joerg, Reiter, A., Hossfeld, D. K., Kolb, H. J., Löffler, H., Pralle, H., Queisser, W., Griesshammer, M., Nerl, C., Kuse, R., Tobler, A., Eimermacher, H., Tichelli, A., Aul, C., Wilhelm, M., Fischer, J. T., Perker, M., Scheid, C., Schenk, M., Weiss, J., Meier, C. R., Kremers, S., Labedzki, L., Schmeiser, T., Lohrmann, H. P., Heimpel, H., Kolb, H.-J. and Lohrmann, H.-P. (2003): Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. In: Leukemia, Vol. 17, Nr. 8: S. 1529-1537

Hasford, Joerg, Pfirrmann, Markus, Hehlmann, R., Baccarani, M., Guilhot, F., Mahon, F. X., Kluin-Nelemans, H. C., Ohnishi, K., Thaler, J. and Steegmann, J. L. (2003): Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. In: Seminars in Hematology, Vol. 40, Nr. 1: S. 4-12

Hasford, Joerg, Pfirrmann, Markus, Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L. and Ansari, H. (3. Juni 1998): A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. In: Journal of the National Cancer Institute, Vol. 90, Nr. 11: S. 850-859

Papakonstantino, G., Bogner, Johannes R., Hofmeister, F. and Hehlmann, R. (1993): Cefotaxime desensitization. In: Clinical Investigator, Vol. 71, Nr. 2: S. 165-167 [PDF, 2MB]

Hehlmann, R., Bogner, Johannes R., Schuster, D. and Lengenfelder, E. (1990): Die AIDS-Tumoren. In: Verhandlungen der Deutschen Gesellschaft für Innere Medizin, Vol. 96: S. 534-539 [PDF, 1MB]

Matuschke, A., Heinrich, B., Hehlmann, R., Bogner, Johannes R. and Füßle, H. S. (1989): Zusammenstellung der gebräuchlichen Definitionen und Klassifikationssysteme bei HIV-Infektion. In: Aids-Forschung, Vol. 4: S. 587-594 [PDF, 36MB]

Diese Liste wurde am Tue Apr 24 20:51:01 2018 CEST erstellt.